Grants per year
Personal profile
Training Experience
| 1996 | Fellowship, Wayne State University |
| 1999 | Internship, Wayne State University |
| 2002 | Residency, University of Chicago Hospitals |
| 2004 | Fellowship, University of Chicago Hospitals |
Education/Academic qualification
MD, Medicine, Medical Academy, Sofia, Bulgaria
… → 1991
Fingerprint
Dive into the research topics where Roumen Deltchev Balabanov is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Northwestern Multiple Sclerosis/Neuroimmunology Fellowship
National Multiple Sclerosis Society
7/1/23 → 6/30/24
Project: Research project
-
Identifying Immune Cell Surface Markers in Multiple Sclerosis and Other Autoimmune Diseases of the Nervous System
3/22/19 → 3/22/24
Project: Research project
-
Northwestern Multiple Sclerosis/Neuroimmunology Fellowship
National Multiple Sclerosis Society
7/1/22 → 6/30/23
Project: Research project
-
Northwestern MS/Neuroimmunology fellowship proposal
National Multiple Sclerosis Society
7/1/21 → 6/30/22
Project: Research project
-
Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study (CNS Drugs, (2022), 36, 9, (977-993), 10.1007/s40263-022-00950-0)
Perumal, J., Balabanov, R., Su, R., Chang, R., Balcer, L. J., Galetta, S. L., Avila, R. L., Rutledge, D. & Fox, R. J., 2023, (Accepted/In press) In: CNS Drugs.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing–Remitting Multiple Sclerosis: STRIVE Data Analysis
Perumal, J., Balabanov, R., Balcer, L., Galetta, S., Sun, Z., Li, H., Rutledge, D., Avila, R. L. & Fox, R. J., Jun 2023, In: Neurology and Therapy. 12, 3, p. 833-848 16 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Neurologic Manifestations of Long COVID Differ Based on Acute COVID-19 Severity
Perez Giraldo, G. S., Ali, S. T., Kang, A. K., Patel, T. R., Budhiraja, S., Gaelen, J. I., Lank, G. K., Clark, J. R., Mukherjee, S., Singer, T., Venkatesh, A., Orban, Z. S., Lim, P. H., Jimenez, M., Miller, J., Taylor, C., Szymanski, A. L., Scarpelli, J., Graham, E. L., Balabanov, R. D., & 14 others, Jul 2023, In: Annals of neurology. 94, 1, p. 146-159 14 p.Research output: Contribution to journal › Article › peer-review
Open Access7 Scopus citations -
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
NOVA study investigators, Jul 2022, In: The Lancet Neurology. 21, 7, p. 608-619 12 p.Research output: Contribution to journal › Article › peer-review
31 Scopus citations -
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study
Perumal, J., Balabanov, R., Su, R., Chang, R., Balcer, L. J., Galetta, S. L., Avila, R. L., Rutledge, D. & Fox, R. J., Sep 2022, In: CNS Drugs. 36, 9, p. 977-993 17 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations
Datasets
-
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Perumal, J. (Creator), Balabanov, R. D. (Creator), Su, R. (Creator), Chang, R. (Creator), Balcer, L. (Creator), Galetta, S. (Creator), Campagnolo, D. I. (Creator), Avila, R. (Creator), Lee, L. (Creator), Rutledge, D. (Creator), Fox, R. J. (Creator) & Galetta, S. (Creator), Adis Journals, 2021
DOI: 10.6084/m9.figshare.14248406.v1, https://adisjournals.figshare.com/articles/media/Natalizumab_in_Early_Relapsing-Remitting_Multiple_Sclerosis_A_4-Year_Open-Label_Study/14248406/1
Dataset
-
Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE
Perumal, J. (Creator), Fox, R. J. (Creator), Balabanov, R. D. (Creator), Balcer, L. J. (Creator), Galetta, S. (Creator), Makh, S. (Contributor), Santra, S. (Contributor), Hotermans, C. (Creator) & Lee, L. (Creator), figshare, 2019
DOI: 10.6084/m9.figshare.c.4534241, https://springernature.figshare.com/collections/Outcomes_of_natalizumab_treatment_within_3_years_of_relapsing-remitting_multiple_sclerosis_diagnosis_a_prespecified_2-year_interim_analysis_of_STRIVE/4534241
Dataset